Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01613118 · ClinicalTrials.gov registry record · Phase 2
Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
A Phase 2 study, sponsored by Travere Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 109
- Enrollment target
NCT01613118 is a Phase 2 study that has completed, run by Travere Therapeutics. The registered enrollment target is 109 participants.
The verdict
NCT01613118, a Phase 2 study, has completed, sponsored by Travere Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 109 participants
- Enrollment target
Study Summary
This study will investigate whether RE-021 (Sparsentan), a selective dual-acting receptor antagonist with affinity for endothelin (A type) and angiotensin II receptors (Type 1), is safe and effective in treating patients with focal segmental glomerulosclerosis (FSGS).
Interventions
- DRUG Irbesartan
- DRUG RE-021 (Sparsentan)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 109 participants |
| Start Date | 2014-03 |
| Est. Completion | 2024-03-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01613118
The ClinicalTrials.gov registry entry for NCT01613118 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 109 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Travere Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Irbesartan is the first listed.
NCT01613118 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01613118 about?
NCT01613118 is a clinical study titled "Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis". This study will investigate whether RE-021 (Sparsentan), a selective dual-acting receptor antagonist with affinity for endothelin (A type) and angiotensin II receptors (Type 1), is safe and effective in treating patients with focal segmental glomerulosclerosis (FSGS).
What is the current status of trial NCT01613118?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 109 participants. The study started on 2014-03. Estimated completion is 2024-03-25.
What interventions are being tested in trial NCT01613118?
The interventions under investigation include: Irbesartan (DRUG), RE-021 (Sparsentan) (DRUG).
Who is sponsoring clinical trial NCT01613118?
This trial is sponsored by Travere Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.